Edwards Lifesciences (NYSE:EW) Coverage Initiated at UBS Group

Analysts at UBS Group assumed coverage on shares of Edwards Lifesciences (NYSE:EW) in a research note issued to investors on Tuesday, MarketBeat reports. The firm set a “buy” rating and a $110.00 price target on the medical research company’s stock. UBS Group’s price target would suggest a potential upside of 32.20% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup upped their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Barclays reiterated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Up 0.7%

NYSE EW opened at $83.21 on Tuesday. The stock’s 50-day moving average price is $87.74 and its 200-day moving average price is $83.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a market capitalization of $47.91 billion, a P/E ratio of 47.82, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts predict that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,577 shares of company stock valued at $3,855,527 in the last three months. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Viking Global Investors LP bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $238,688,000. Marshall Wace LLP boosted its position in shares of Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after acquiring an additional 2,359,128 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Edwards Lifesciences by 132.4% in the first quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock valued at $310,984,000 after purchasing an additional 2,212,208 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.